Piramal Pharma FY26 Earnings, Impairment

Piramal Group announced its standalone and consolidated financial results for Q4 and the full fiscal year ended March 31, 2026. The company reported a slight decrease in revenue from operations and a significant drop in EBITDA for FY26 compared to FY25. A notable event was the recognition of an impairment loss of ₹176 crore related to intangible assets under development. Despite these challenges, Chairperson Nandini Piramal expressed confidence in a stronger exit to the year and projected accelerated growth in FY27 across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH) businesses. Key business highlights included healthy traction in CDMO order inflows, the acquisition of Kenalog in CHG, and strong growth in PCH's Power Brands and e-commerce sales.